Summary results from the HT-SMRs (n=97 reviews)
| Drug class reviewed | Number of reviews (% of all reviews) | Median DDD of medication reviewed (IQR) | Median duration of use (months) (IQR) | Median CGI-I (IQR)* | Median Modified Efficacy Index (IQR)† |
| Antipsychotic | 49 (51%) | 67 (45–100) | 24 (4–60) | 1.5 (1.0–2.0) | 2.0 (1.0–3.0) |
| Antidepressant | 28 (29%) | 150 (87–200) | 12 (4–24) | 2.0 (1.0–3.0) | 2.0 (1.4–3.0) |
| Anxiolytic/sedative | 9 (9%) | 24 (2–54) | 100 (39–100) | 3.0 (2.0–3.0) | 3.0 (2.3–4.0) |
| Medication for attention deficit hyperactivity disorder | 9 (9%) | 120 (78–138) | 18 (12–78) | 2.0 (1.0–2.5) | 2.0 (1.0–4.0) |
| Mood stabiliser | 2 (2%) | 33 | 96 | 2.5 | 1.2 |
| All | 97 (100%) | 100 (50–133) | 18 (5–56) | 2.0 (1.0–3.0) | 1.5 (1.0–3.0) |
*CGI-I is scored between 1 (very much improved) and 7 (very much worse).
†Modified Efficacy Index is the ratio between the score in the domain with the greatest therapeutic benefit and the score in the domain with the worst rated adverse side-effect. Higher scores indicate more favourable medication response.
ADHD, Attention Deficit Hyperactivity Disorder; CGI-I, Clinical Global Impression-Improvement; DDD, defined daily dose; HT-SMR, HealthTracker-based structured medication review; IQR, interquartile range.